Pregnancy & Lactation : הריון/הנקה

4.6   Fertility, pregnancy and lactation

Women of child-bearing potential
Pregnancy whilst taking mycophenolate must be avoided. Therefore, women of childbearing potential must use at least one form of reliable contraception (section 4.3) before starting Myfortic therapy, during therapy, and for six weeks after stopping the therapy, unless abstinence is the chosen method of contraception. Two complementary forms of contraception simultaneously are preferred.

Pregnancy

Myfortic is contraindicated during pregnancy unless there is no suitable alternative treatment available to prevent transplant rejection. Treatment should not be initiated without providing a negative pregnancy test result to rule out unintended use in pregnancy.

Female patients of reproductive potential must be made aware of the increased risk of pregnancy loss and congenital malformations at the beginning of the treatment and must be counseled regarding pregnancy prevention and planning.


MYF API March23 V3                                                                           REF UK SmPC March23 Before starting Myfortic treatment, women of child-bearing potential should have two negative serum or urine pregnancy tests with a sensitivity of at least 25 mIU/mL in order to exclude unintended exposure of the embryo to mycophenolate. It is recommended that the second test should be performed 8 – 10 days after the first test. For transplants from deceased donors, if it is not possible to perform two tests 8-10 days apart before treatment starts (because of the timing of transplant organ availability), a pregnancy test must be performed immediately before starting treatment and a further test performed 8-10 days later. Pregnancy tests should be repeated as clinically required (e.g. after any gap in contraception is reported).
Results of all pregnancy tests should be discussed with the patient. Patients should be instructed to consult their physician immediately should pregnancy occur.

Mycophenolate is a powerful human teratogen, with an increased risk of spontaneous abortions and congenital malformations in case of exposure during pregnancy: 
      Spontaneous abortions have been reported in 45 to 49% of pregnant women exposed to mycophenolate mofetil, compared to a reported rate of between 12 and 33% in solid organ transplant patients treated with immunosuppressants other than mycophenolate mofetil.
      Based on literature reports, malformations occurred in 23 to 27% of live births in women exposed to mycophenolate mofetil during pregnancy (compared to 2 to 3 % of live births in the overall population and approximately 4 to 5% of live births in solid organ transplant recipients treated with immunosuppressants other than mycophenolate mofetil).

Congenital malformations, including reports of multiple malformations, have been observed post-marketing in children of patients exposed to Myfortic in combination with other immunosuppressants during pregnancy. The following malformations were most frequently reported:
•     Abnormalities of the ear (e.g., abnormally formed or absent external), external auditory canal atresia (middle ear);
•     Facial malformations such as cleft lip, cleft palate, micrognathia and hypertelorism of the orbits;
•     Abnormalities of the eye (e.g., coloboma);
•     Congenital heart disease such as atrial and ventricular septal defects;
•     Malformations of the fingers (e.g., polydactyly, syndactyly);
•     Tracheo-Oesophageal malformations (e.g., oesophageal atresia);
•     Nervous system malformations such as spina bifida;
•     Renal abnormalities.

In addition there have been isolated reports of the following malformations:
•     Microphthalmia;
•     congenital choroid plexus cyst;
•     septum pellucidum agenesis;
•     olfactory nerve agenesis.

Studies in animals have shown reproductive toxicity (see section 5.3).
Men
Limited clinical evidence does not indicate an increased risk of malformations or miscarriage following paternal exposure to mycophenolate mofetil.
MPA is a powerful teratogen. It is not known if MPA is present in semen. Calculations based on animal data show that the maximum amount of MPA that could potentially be transferred to woman is so low that it would be unlikely to have an effect. Mycophenolate has been shown to be genotoxic in animal studies at concentrations exceeding the human therapeutic exposures by small margins, such that the risk of genotoxic effects on sperm cells cannot completely be excluded.

MYF API March23 V3                                                                             REF UK SmPC March23 Therefore, the following precautionary measures are recommended: sexually active male patients or their female partners are recommended to use reliable contraception during treatment of the male patient and for at least 90 days after cessation of mycophenolate. Male patients of reproductive potential should be made aware of and discuss the potential risks of fathering a child with a qualified health-care professional.

Breastfeeding
MPA is excreted in milk in lactating rats. It is unknown whether Myfortic is excreted in human breast milk. Because of the potential for serious adverse reactions to MPA in breast- fed infants, Myfortic is contra-indicated in women who are breast-feeding (see section 4.3).

Fertility
No specific studies with Myfortic in humans have been conducted to evaluate effects on fertility. In a study on male and female fertility in rats no effects were seen up to a dose of 40 mg/kg and 20 mg/kg respectively (see section 5.3).